KBI Biopharma, Inc. Continues to Strengthen Leadership and Expertise With Key Executive Appointments
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced four recent executive appointments to continue its momentum and vision of becoming a next-generation CDMO. Joining the company are Tony Fraij, Chief Operating Officer; Shaguna Seth, Chief of Staff and Global PMO Leader; Katie Edgar, Senior Vice President of Corporate Strategy and Alliance Management; and Sarah Wakefield, Senior Vice President, Corporate Communications.
“I am thrilled to welcome these four exceptional experts to KBI. Each of them brings unique insight, has an impressive track record, and is fully aligned with our KBI vision as we navigate the evolving landscape of our industry and seize opportunities for success,” said J.D. Mowery, KBI Biopharma CEO. “They will all play vital roles in shaping our future at KBI, enabling us to be the best and most trusted partner to our global biopharmaceutical customers.”
Tony Fraij
As KBI's Chief Operating Officer, Fraij brings extensive experience as an operations leader of multiple global pharmaceutical and biotech companies. He will utilize his expertise in personnel development, engineering, and technical operations to strategically guide KBI's daily operations, ensuring optimal efficiencies and supporting company growth. He will lead operations teams globally, including Manufacturing, IT, and Engineering. Fraij previously served as Senior Vice President and General Manager at AGC Biologics, Vice President of Technical Operations at Novartis, and Director of Operations at Boehringer Ingelheim. Throughout his career, Fraij introduced new process development capabilities globally, led multi-disciplinary teams overseeing operational safety and compliance, and implemented digital strategies to improve technical operations.
Shaguna Seth
As KBI’s Chief of Staff, Seth is a seasoned business and technology executive who excels at driving operational execution and performance. In her new role, she will leverage more than two decades of experience in translational research, pharmaceutical development, manufacturing, and program management and has successfully collaborated with a diverse range of clients, applying her expertise in biologics and RNA-based drug development. She holds numerous patents targeting various disease areas that will allow her to be a productive executive team member and establish a world-class PMO. She previously served as AGC Biologics’ Interim General Manager and VP of Process Development.
Katie Edgar
In her role as Senior Vice President of Corporate Strategy and Alliance Management, Edgar will work closely with the KBI and JSR Life Science teams to identify strategic growth initiatives and opportunities, elevate partnership management and performance, and help fulfill the company’s industry-leading vision. With her background in strategy and operations, business development, mergers and acquisitions, and portfolio and alliance management, she will provide crucial support in aligning objectives across the KBI and JSR networks and propel KBI’s transformation plan forward.
Sarah Wakefield
In her newly created role as Senior Vice President, Corporate Communications, Wakefield brings 20 years of experience to KBI, with many of those years spent in the healthcare and biotech industries. Her expertise lies in building high-performing marketing and communications teams and processes that effectively increase brand awareness, drive revenue growth, enhance communications, and foster an inclusive culture. With a proven record of success, she will contribute valuable leadership skills in executive strategy, marketing, branding and identity, DEI initiatives, project management, and organizational and team development.
About KBI Biopharma, Inc.
KBI Biopharma, Inc., a JSR Life Sciences company, together with its affiliates, is a global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. As a global leader in mammalian cell line development, with best-in-class modular technology and highly specialized solutions, KBI enables the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. With each of its 500+ client partners, KBI works closely to personalize and rapidly accelerate drug development programs.
Global partners are utilizing KBI’s technologies to advance more than 160 drug candidates in preclinical and clinical development and the manufacture of ten commercial products. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Recognized for quality manufacturing, KBI helps partners advance drug candidates to the market. KBI serves its global partners with eight locations in Europe and the USA. More information is available at www.kbibiopharma.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230810847673/en/
Contact information
KBI Biopharma, Inc. Company Inquiries
Sarah Wakefield
KBI Biopharma, Inc.
swakefield@kbibiopharma.com
KBI Biopharma, Inc. Media Inquiries
Blair Ciecko
CG Life
bciecko@cglife.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
30 Peer-Reviewed Studies Highlight Statistically Significant Health Benefits of Almased16.7.2025 10:15:00 EEST | Press release
Two recent, peer-reviewed clinical studies have found that Almased, a high-protein, low-glycemic meal replacement, delivers significant health benefits ranging from weight loss and improved metabolic health to anti-aging effects and enhanced quality of life. Both reviews synthesize 30 peer-reviewed clinical studies across three decades of scientific research, confirming that Almased is effective and safe for weight reduction, preservation of lean muscle mass, and cardiovascular health. The 2025 review in the American Journal of Biomedical Science & Research highlighted Almased’s efficacy and safety for wide groups of people including individuals seeking weight loss, those with metabolic syndrome or fatty liver, older adults needing to preserve muscle mass, and athletes or healthy-weight individuals who require additional high-quality protein. This review also discusses how Almased’s patented fermentation process produces over 80 bioactive peptides, including 2 times the average daily i
Skechers AERO Series Opens New Chapter of Technical Running Innovation16.7.2025 10:00:00 EEST | Press release
Skechers Performance opens a new chapter of running innovation with the arrival of the Skechers AERO series. Named for the aerodynamic feel of the design, Skechers AERO represents the latest evolution of technical running shoes from the brand. The collection is engineered to deliver an exhilarating blend of speed, style and comfort to help runners cut through the wind and push beyond their personal bests while logging miles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716754749/en/ Introducing the Skechers AERO Series of technical running shoes: Skechers AERO Burst, Skechers AERO Spark, and Skechers AERO Tempo (L-R). “Recently launched in North America and Asia, the AERO Series leverages innovative technologies to elevate our signature comfort that’s now available to runners in Europe,” said Ben Stewart, Vice President, Skechers Technical Performance Division. “An evolution of our legacy in running, Skechers AERO was d
The Future of Connectivity Starts Here: Network X Returns to Paris October 14 - 1616.7.2025 10:00:00 EEST | Press release
Network X 2025 - the only event that brings the fixed and mobile markets together - returns to Paris Expo Porte de Versailles October 14 - 16. Built for telecom's top players, this annual show drives business model innovation and monetisation of next-generation fixed, mobile, satellite and transport networks through AI and cloud. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716595903/en/ Speaker on Headliners Stage at Network X 2024 New to Network X in 2025 are specialty events designed to deliver expert insights on trending topics including Data Center World and two Expo Stages for Fixed-Line and Mobile. More than 5,500 telco network infrastructure professionals will gather alongside 1,500 telcos to learn from six program tracks highlighting the latest advancements in Fibre, Wi-Fi Networks and Services, IP and Optical Transport, Mobile Networks, Mobile Services, and Data Centres. “Network X is more than a conference—it
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 08:00:00 EEST | Press release
4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P004. “Enrolling our first patient is a pivotal step toward rewriting the treatment paradigm for knee osteoarthritis,” said Professor Francis Berenbaum, MD, PhD, Chief Medical Officer at 4Moving Biotech. “Almost 600 million people live with OA, yet no disease-modifying therapy has been done to patients. B
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 20:06:00 EEST | Press release
Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The company’s global headquarters includes WPC certified test equipment and state-of-the-art test labs dedicated to full product lifecycle validatio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom